Beyond GLP-1: 3 New Experimental Weight Loss Drugs to Watch
Three experimental weight loss medications—EloraTZP, trevogrumab, and CBL-514—drew attention this week at the annual meeting of the European Association for the Study of Diabetes, showcasing new biological approaches to obesity treatment that go beyond traditional GLP-1 therapies.
- EloraTZP combined tirzepatide and eloralintide in a phase 2 trial, driving an average weight loss of up to 54.1 pounds or 23.3 percent of body weight in adults with obesity or overweight and type 2 diabetes.
- Trevogrumab acts as a monoclonal antibody blocking myostatin, helping patients taking semaglutide preserve more than 70 percent of their muscle mass loss compared to semaglutide alone in a trial of more than 1,000 patients.
- CBL-514 takes a novel cellular approach by inducing apoptosis in adipocytes, reducing subcutaneous fat by 150 milliliters in nearly 70 percent of participants at an eight-week follow-up during a phase 2 trial.
Why Are Scientists Focusing on New Diabetes and Obesity Drugs Now?
The field of obesity and diabetes medicine is evolving rapidly during the GLP-1 era as researchers push past single-hormone mechanisms. Numerous active molecules are currently under evaluation, and Christine Gallagher, the associate director for research and policy for the STOP Obesity Alliance at George Washington University’s Milken Institute School of Public Health in Washington, DC, pointed out that the sector keeps growing. Alongside these emerging phase 2 candidates, late-stage phase 3 trial data for retatrutide—a once-a-week injectable often dubbed a “Godzilla” drug and expected to become a blockbuster ahead of expected FDA review next year—generated substantial buzz at the European Association for the Study of Diabetes annual meeting.
How Does EloraTZP Compare to Tirzepatide Alone in Clinical Trials?
Developed by Eli Lilly, the pharmaceutical company behind Zepbound, Mounjaro, and the Foundayo pill (orforglipron), EloraTZP is a once-a-week injectable combining tirzepatide with eloralintide. Tirzepatide mimics the natural hormones GLP-1 and GIP, while eloralintide mimics amylin. Together, these compounds regulate blood sugar, control appetite, and slow digestion.
In a phase 2 clinical trial involving nearly 400 adults with obesity or overweight and type 2 diabetes, participants receiving EloraTZP achieved an average weight loss of up to 54.1 pounds, representing 23.3 percent of their body weight. By contrast, participants taking a 15 mg dose of tirzepatide alone lost an average of 34.4 pounds, or 14.8 percent of body weight. Patients on EloraTZP lowered their A1C by an average of 2.9 percent, compared with a 2.4 percent reduction for those taking tirzepatide alone.
Regarding safety profiles, EloraTZP users experienced predominantly gastrointestinal adverse events, which caused up to 27 percent of participants to discontinue treatment. According to Richard Siegel, MD, an endocrinologist at Tufts Medicine Weight & Wellness Center in Stoneham, Massachusetts, and a codirector of the Diabetes and Lipid Center at Tufts Medical Center, the adverse events and weight loss efficacy remain on par with other second-generation anti-obesity treatments. Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, California, added that targeting additional hormone receptors can increase both therapeutic efficacy and side effect frequency.
Can Trevogrumab Prevent Muscle Loss During Semaglutide Treatment?
Trevogrumab functions differently by targeting preservation of lean mass rather than directly driving weight loss. As a monoclonal antibody designed to block myostatin—a protein tied to muscle mass loss—it is administered alongside semaglutide, the active ingredient in Wegovy and Ozempic. Trial results utilized MRI scans of the thigh muscles of more than 1,000 patients.
After 52 weeks, patients receiving a 75-milligram dose of trevogrumab alongside semaglutide preserved more than 70 percent of their muscle mass loss compared to those taking semaglutide alone. During the initial 26-week phase, participants on semaglutide alone lost 6.7 percent of their lean muscle mass, whereas those receiving the combination lost only 3.3 percent. Participants who discontinued semaglutide while maintaining trevogrumab saw their muscle mass return to where it was before they started semaglutide.
Dr. Ali noted that minimizing muscle loss preserves strength and maintains resting metabolic rate, given that muscle tissue burns more calories at rest. Conversely, Dr. Siegel cautioned that it remains unproven whether reduced muscle loss directly translates to improved functional strength and mobility for patients.
How Does CBL-514 Destroy Fat Cells Without Hormone Receptors?
While standard anti-obesity medications alter appetite signaling and digestion via hormone receptors, CBL-514 targets fat tissue directly by inducing apoptosis of adipocytes to destroy fat cells. A phase 2 clinical trial randomized 40 patients with obesity to receive injections of CBL-514 or a placebo into the lower abdomen every three weeks for up to 12 weeks, with injection frequencies decreasing as fat thickness diminished.
Using MRI scans to measure adipose tissue at baseline and at 4, 8, and 12 weeks post-treatment, researchers observed that CBL-514 reduced subcutaneous adipose tissue by 150 milliliters in nearly 70 percent of participants by the eight-week follow-up. None of the participants receiving the placebo reached this benchmark.
What Do Physicians Anticipate for Future Obesity Treatments?
Clinical specialists expect the expanding therapeutic pipeline to increase treatment versatility and affordability. Dr. Siegel stated that an expanded range of approved medications should help drive down costs and broaden coverage across insurance plans. Dr. Ali emphasized that individual patient responses vary significantly, making a diverse selection of mechanisms essential for clinical practice.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.